Preview

Медицинский Совет

Расширенный поиск

ПЕМБРОЛИЗУМАБ В ЛЕЧЕНИИ МЕТАСТАТИЧЕСКОЙ МЕЛАНОМЫ

https://doi.org/10.21518/2079-701X-2017-6-8-23

Полный текст:

Аннотация

В настоящее время в России появляются лекарственные препараты нового класса – модуляторы иммунологического синапса (МИС), наиболее эффективными среди которых являются блокаторы PD-1. Пембролизумаб – эффективный противоопухолевый препарат, моноклональное антитело, которое блокирует сигнальную молекулу PD1 на цитотоксическом лимфоците, подавляющую противоопухолевый иммунный ответ. Пембролизумаб может успешно применяться в первой и последующих линиях терапии метастатической меланомы кожи вне зависимости от наличия активирующих мутаций в гене BRAF и других молекулярных маркеров. Рекомендуемый режим применения в настоящее время – 2 мг/кг внутривенно каждые 3 недели длительно до развития непереносимости или явного прогрессирования заболевания. В настоящем обзоре систематизированы сведения об эффективности и безопасности применения пембролизумаба у больных метастатической меланомой, приведенные в разнообразных клинических исследованиях и ретроспективных наблюдениях.

Об авторах

И. В. САМОЙЛЕНКО
Российский онкологический научный центр им. Н.Н. Блохина Минздрава России
Россия
к.м.н.


Л. В. ДЕМИДОВ
Российский онкологический научный центр им. Н.Н. Блохина Минздрава России
Россия
д.м.н., профессор


Список литературы

1. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, 15(23): 7412-7420.

2. Самойленко И.В., Харкевич Г.Ю., Демидов Л.В. Преодоление иммунной толерантности как способ лечения злокачественных опухолей: новые перспективы. Современная онкология, 2014, 16(1): 42-47.

3. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45(2): 228-247.

4. Van Hoe L, Van Cutsem E, Vergote I, Marchal G, Baert AL. Reporting on the results of cancer treatment in patients with metastatic liver disease: proposal of symmetric size- dependent CT-criteria for response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996, 7(8): 871-872.

5. Kurth K. The application of response criteria on reporting treatment results in cancer trials. Prog Clin Biol Res, 1990, 359: 49-64, discussion 73-44.

6. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine, 2010, 363(8): 711-723.

7. Lotze TM, Dallal RM, Kirkwood JM, Flickinger JC: Cutaneous Melanoma. In: Cancer: Principles and Practice of Oncology 6th edition. edn. Edited by Devita VT, Hellman S, Rosenberg SA: Lippincott Williams & Wilkins.

8. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr., Kirkwood JM et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, 19(16): 3635-3648.

9. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, 19(16): 3622-3634.

10. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression- free and overall survival benchmarks for future phase II trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2008, 26(4): 527-534.

11. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, 33(17): 1889-1894.

12. Larkin J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J, Cowey CL, Lao CD, Schadendorf D, Ferrucci PF, Smylie M et al. Overall Survival Results From a Phase III Trial of Nivolumab Combined With Ipilimumab in Treatment-naïve Patients With Advanced Melanoma (CheckMate 067). In: AACR Annual Meeting: April 1-5 2017, Walter E. Washington Convention Center, Washington, D.C., USA, 2017.

13. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol, 2015, 15(1): 45-56.

14. Markwick LJ, Riva A, Ryan JM, Cooksley H, Palma E, Tranah TH, Manakkat Vijay GK, Vergis N, Thursz M, Evans A et al. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. Gastroenterology, 2015, 148(3): 590- 602 e510.

15. Ribas A, Tumeh PC. The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, 20(19): 4982-4984.

16. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol, 2009, 21(9): 1065-1077.

17. van Wijk F, Nierkens S, de Jong W, Wehrens EJ, Boon L, van Kooten P, Knippels LM, Pieters R. The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins. J Immunol, 2007, 178(11): 6894-6900.

18. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, 19(19): 5300-5309.

19. Jin R. Clinical Pharmacology BLA Review 125514. In. 2014.

20. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA, 2016, 315(15): 1600-1609.

21. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Oral prresentation on ASCO 2016 Annual Meeting. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 34(suppl; abstr 9503).

22. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab- refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet Oncology, 2015, 16(8): 908-918.

23. Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC et al. Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Annals of Oncology, 2016, 27(suppl_6): 1107O-1107O.

24. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England journal of medicine, 2015, 372(26): 2521-2532.

25. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall

26. survival analysis of KEYNOTE-006. In: 2016 ASCO Annual Meeting: 2016; Chicago, Illinois, USA; 2016: J Clin Oncol 34, 2016 (suppl; abstr 9504).

27. Hodi FS, Kluger H, Sznol M, Carvajal R, Lawrence D, Atkins M, Powderly J, Sharfman W, Puzanov I, Smith D et al. Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research: April 1-5 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA), 2016 Apr 16-20: Abstract nr CT001.

28. Furmark L, Pavlick A: BRAF Inhibitors and the «Lazarus Syndrome» – An Update and Perspective. Am J Hemat Oncol, 2015, 11(4): 24-29.

29. Frank GA, Aleksakhina SN, Zavalishina LE, Kekeyeva TV, Venina AR, Ivantsov AO, Mitiushkina NV, Moiseyenko AV, Pfeifer W, Strelkova TN et al. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study. Melanoma Res, 2016, 26(5): 442- 447.

30. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine, 2011, 364(26): 2507-2516.

31. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Jr., Kaempgen E et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2012, 380(9839): 358-365.

32. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet, 2015, 386(9992): 444-451.

33. Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation- positive melanoma (COMBI-v): results of a phase 3, open-label,randomised trial. The Lancet Oncology, 2015,16(13): 1389-1398.

34. Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandala M, Demidov L, Stroyakovskiy D, Thomas L et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. The Lancet Oncology, 2016, 17(9): 1248-1260.

35. Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ et al. The efficacy of anti- PD-1 agents in acral and mucosal melanoma. Cancer, 2016, 122(21): 3354-3362.

36. Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer, 2016, 122(21): 3344-3353.

37. Dagogo-Jack I, Lanfranchi M, Gainor JF, Giobbie-Hurder A, Lawrence DP, Shaw AT, Sullivan RJ. A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis. Journal of immunotherapy, 2017, 40(3): 108-113.

38. Nosrati A, Tsai KK, Goldinger SM, Tumeh P, Grimes B, Loo K, Algazi AP, Nguyen-Kim TDL, Levesque M, Dummer R et al. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer, 2017, 116(9): 1141-1147.

39. Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A et al. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2015, 26(11): 2267- 2274.

40. Schadendorf D. Efficacy and quality of life outcomes in patients with advanced melanoma (MEL) who discontinued treatment with niovlumab (NIVO) plus ipilimumab (IPI) due to toxicicty in a phase III trial (CheckMate 067). In: 2016 Annual Meeting of the European Association of Dermatoonocolgy: August 31 - September 03, 2016 2016; Vienna, Austria, 2016.

41. Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol, 2014, 11(2): 91-99.

42. Full prescribing information Keytruda® (pembrolizumab) for injection, for intravenous use. In. Edited by Administration UFaD, 2016.

43. Харкевич Г.Ю., Орлова К.В. Иммуноопосредованные нежелательные явления ингибиторов блокаторов иммунного ответа. Практическая онкология, 2016, 17(2): 110- 118.

44. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, 30(21): 2691-2697.


Просмотров: 129


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)